Stockscreener 앱 받기
1.06
0.93%
-0.01
전일 마감가:
$1.07
열려 있는:
$1.07
하루 거래량:
8,563
Relative Volume:
0.05
시가총액:
$8.66M
수익:
$4.83M
순이익/손실:
$-2.99M
주가수익비율:
-2.2065
EPS:
-0.4804
순현금흐름:
$-2.83M
1주 성능:
-14.52%
1개월 성능:
+6.00%
6개월 성능:
+12.29%
1년 성능:
-38.37%
1일 변동 폭
$1.036
$1.07
1주일 범위
$1.02
$1.22
52주 변동 폭
$0.6765
$2.39
이뮤론 Stock (IMRN) Company Profile
Compare IMRN vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMRN
Immuron Limited Adr
|
1.06 | 8.66M | 4.83M | -2.99M | -2.83M | -0.4804 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
이뮤론 주식(IMRN)의 최신 뉴스
Which stocks have an unusual volume on Thursday? - ChartMill
Immuron (NASDAQ: IMRN) responds to ASX query on share price - Stock Titan
Wondering what's happening in today's after-hours session? - ChartMill
Immuron (IMRN) CCO reports 1.14M shares and 640K performance rights in Form 3 - Stock Titan
Number of shareholders of Immuron Limited Sponsored ADR – LSX:A2DTD8 - TradingView
Immuron (NASDAQ: IMRN) details TD portfolio growth and partnering push - Stock Titan
Immuron (IMRN) chairman discloses 1.67M share options - Stock Titan
Immuron (NASDAQ: IMRN) CEO schedules Emerging Growth Conference presentation - Stock Titan
IMRN - Finviz
Unusual VolumeStock ScreenerNews - Finviz
IMRN Stock Price, Quote & Chart | IMMURON LTD-SPON ADR (NASDAQ:IMRN) - ChartMill
Immuron Double Digit 3Q Sales Growth - Sahm
Top 10 at 11: Wall Street hits all-time highs but ASX opens lower as banks retreat - MSN
Immuron (NASDAQ: IMRN) lifts Travelan sales with strong Canada Q3 surge - Stock Titan
Immuron (NASDAQ: IMRN) offers cost-free sale facility for small shareholdings - Stock Titan
Operating cash flow per share of Immuron Limited Sponsored ADR – GETTEX:ANWA - TradingView
Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.90 Price Target - Democrat and Chronicle
IMRN Earnings History & Surprises | EPS & Revenue Results | IMMURON LTD-SPON ADR (NASDAQ:IMRN) - ChartMill
Immuron CEO, Steven Lydeamore presentation at Coffee Microcaps Conference - Sahm
Immuron (NASDAQ: IMRN) boosts cash, pursues partners for IMM-124E and IMM-529 - Stock Titan
Immuron Reports HY26 Results and Strategic Reset - GlobeNewswire Inc.
Immuron Reports HY26 Results and Strategic Reset - ChartMill
Immuron (NASDAQ: IMRN) gains A$1.12M non-dilutive R&D refund - Stock Titan
Immuron (NASDAQ: IMRN) shareholders back ratification of prior share issues - Stock Titan
Immuron Limited (IMRN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.50 Price Target - progress-index.com
Immuron Reports Continued Sales Growth - Finviz
Why B. Riley Financial Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket - Benzinga
[6-K] Immuron Ltd Current Report (Foreign Issuer) | IMRN SEC FilingForm 6-K - Stock Titan
Immuron Limited Announces Quotation of New Securities on ASX - The Globe and Mail
Immuron stock tumbles after trial fails to meet primary endpoint By Investing.com - Investing.com Australia
Immuron stock tumbles after trial fails to meet primary endpoint - Investing.com India
These stocks that are showing activity before the opening bell on Wednesday. - ChartMill
Why UiPath Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket - Benzinga
Immuron Limited (IMRN) Plunges Amidst Management Uncertainty and Bearish Market Sentiment - FinancialContent
Wondering what's happening in today's pre-market session? - ChartMill
Immuron Reports Strong FY2025 Results and Outlines FY2026 Plans - TipRanks
Immuron IMM-529 IND approved by FDA - FinancialContent
Insights: Immuron Ltd (ASX:IMC) - smallcaps.com.au
IMRN furnishes 6-K with ASX updates and Exhibit 99.1 - Stock Titan
Immuron Submits IMM-529 IND to FDA - GlobeNewswire
Immuron (IMRN) Posts 49% FY2025 Revenue Growth on Travelan Sales - Finviz
Immuron Limited Releases Corporate Governance Statement - The Globe and Mail
Immuron: Targeted oral antibodies to treat infectious diseases - Innovation News Network
이뮤론 (IMRN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.74%
1.44%
자본화:
|
볼륨(24시간):